Related Experiment Video

Updated: Oct 3, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy

Lindsey D Mayo1, Jack E Dixon, Donald L Durden

  • 1Department of Microbiology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.

The Journal of Biological Chemistry
|December 1, 2001
PubMed

Insights

The PTEN tumor suppressor protein enhances p53

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • PTEN (phosphatase and tensin homolog) is a critical tumor suppressor.
  • PTEN regulates the PI3K/Akt pathway, influencing cell growth and survival.
  • p53 is a key tumor suppressor protein, often called the "guardian of the genome".

Purpose of the Study:

  • To investigate the functional relationship between PTEN and p53.
  • To determine if PTEN influences p53 activity and cellular response to stress.
  • To explore the potential of PTEN in sensitizing glioblastoma cells to chemotherapy.

Main Methods:

  • Utilized retroviral transduction to introduce PTEN into PTEN-null U87MG glioblastoma cells.
  • Assessed p53 protein levels, activity, and target gene expression.
  • Evaluated cell cycle arrest and sensitivity to etoposide-induced DNA damage.

Main Results:

  • PTEN inhibits Mdm2 nuclear translocation, leading to increased p53 stability and activity.
  • PTEN-expressing U87MG cells showed enhanced p53 activity, cell cycle arrest, and increased sensitivity to etoposide.
  • Demonstrated a direct functional link between PTEN and p53, challenging the notion of individual tumor suppressor action.

Conclusions:

  • PTEN and p53 act synergistically to suppress tumors and respond to cellular stress.
  • PTEN protects p53, amplifying cellular anti-cancer responses and potentially sensitizing tumors to DNA-damaging chemotherapy.
  • A positive feedback loop between p53 and PTEN may enhance cellular defense mechanisms against cancer development.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...